Contents

Search

filgrastim-sndz (Zarxio)

Biosimilar to filgrastim FDA-approved March 2015 [1] first biosimilar product approved in the United States Indications: - neutropenia (same of filgrastim) - myelosuppressive chemotherapy - acute myeloid leukemia with induction or consolidation chemotherapy - cancer patients undergoing bone marrow transplantation - autologous peripheral blood progenitor cell collection & therapy - severe chronic neutropenia

Related

G

General

filgrastim [G-CSF] (Neupogen, Lenograstim, Granulokine) biosimilar

References

  1. FDA News Release. March 6, 2015 FDA approves first biosimilar product Zarxio http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm